SLC5A2 and diabetic kidney disease: SGLT-2 inhibitors have shown cardiovascular and renal benefits beyond glycemic effects.1, 2, 3, 4, 5, 6, 7 The renoprotective effects of SGLT-2 inhibitors attenuate the progression of diabetic nephropathy and reduce risk of adverse renal outcomes in patients with T2DM.1